ProBio: An outcome-adaptive, multi-arm, open-label, multiple assignment randomised controlled biomarker-driven trial in patients with metastatic castration-resistant prostate cancer

被引：0
|
作者：
Lindberg, J. [1 ]
De Laere, B. [1 ]
Crippa, A. [1 ]
Eklund, M. [1 ]
Gronberg, H. [1 ]
机构：
[1] Karolinska Inst, Med Epidemiol & Biostat, Stockholm, Sweden
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
基金：
瑞典研究理事会;
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
896TiP
引用
收藏
页码：354 / 354
页数：1
相关论文
共 50 条
  • [1] Efficacy of carboplatin in patients with metastatic castration-resistant prostate cancer: Results from the biomarker-driven, randomised, outcome-adaptive ProBio trial
    Kristiansen, A.
    Sautois, B.
    Crippa, A.
    Mortezavi, A.
    Discacciati, A.
    Karlsson, C. T.
    Ullen, A.
    Janes, E.
    Enblad, G.
    Oldenburg, J.
    Sandzen, J.
    Vigmostad, M. N.
    Hjalm-Eriksson, M. E.
    De Laere, B.
    Strijbos, M. H.
    Ghysel, C.
    Lindberg, J.
    Eklund, M.
    Ost, P.
    Gronberg, H.
    ANNALS OF ONCOLOGY, 2024, 35 : S978 - S978
  • [2] Clinical Trial Protocol for ProBio: An Outcome-adaptive and Randomised Multiarm Biomarker-driven Study in Patients with Metastatic Prostate Cancer
    De laere, Bram
    Crippa, Alessio
    Discacciati, Andrea
    Larsson, Berit
    Oldenburg, Jan
    Mortezavi, Ashkan
    Ost, Piet
    Eklund, Martin
    Lindberg, Johan
    Gronberg, Henrik
    EUROPEAN UROLOGY FOCUS, 2022, 8 (06): : 1617 - 1621
  • [3] Androgen receptor pathway inhibitors or taxanes for patients with metastatic castration-resistant prostate cancer: A direct comparison in ProBio, a randomized, outcome-adaptive, biomarker-driven platform trial
    Gronberg, H.
    Lindberg, J.
    De laere, B.
    Crippa, A.
    Discacciati, A.
    Karlsson, C. T.
    Ullen, A.
    Janes, E.
    Mortezavi, A.
    Ost, P.
    Enblad, G.
    Oldenburg, J.
    Sandzen, J.
    Pettersson, L.
    Vigmostad, M. N.
    Hjalm-Eriksson, M. E.
    Olsson, M.
    Schatteman, P.
    Ghysel, C.
    Eklund, M.
    ANNALS OF ONCOLOGY, 2023, 34 : S1327 - S1327
  • [4] An Open-Label, Single-Arm Phase Two Trial of Gefitinib in Patients With Advanced or Metastatic Castration-Resistant Prostate Cancer
    Pezaro, Carmel
    Rosenthal, Mark A.
    Gurney, Howard
    Davis, Ian D.
    Underhill, Craig
    Boyer, Michael J.
    Kotasek, Dusan
    Solomon, Benjamin
    Toner, Guy C.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2009, 32 (04): : 338 - 341
  • [5] A phase II, open-label, multi-arm study of TAS-115 for castration-resistant prostate cancer patients with bone metastases.
    Uemura, Hiroji
    Matsubara, Nobuaki
    Uemura, Hirotsugu
    Nagamori, Satoshi
    Suzuki, Hiroyoshi
    Kimura, Go
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [6] A Phase II, Randomized, Open-Label, Multi-arm Study of TAS-115 for Castration-Resistant Prostate Cancer Patients With Bone Metastases
    Matsubara, Nobuaki
    Uemura, Hirotsugu
    Nagamori, Satoshi
    Suzuki, Hiroyoshi
    Uemura, Hiroji
    Kimura, Go
    CLINICAL GENITOURINARY CANCER, 2021, 19 (06) : 491 - 500
  • [7] Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial
    Chi, Kim N.
    Higano, Celestia S.
    Blumenstein, Brent
    Ferrero, Jean-Marc
    Reeves, James
    Feyerabend, Susan
    Gravis, Gwenaelle
    Merseburger, Axel S.
    Stenzl, Arnulf
    Bergman, Andries M.
    Mukherjee, Som D.
    Zalewski, Pawel
    Saad, Fred
    Jacobs, Cindy
    Gleave, Martin
    de Bono, Johann S.
    LANCET ONCOLOGY, 2017, 18 (04): : 473 - 485
  • [8] Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
    de Bono, Johann Sebastian
    Oudard, Stephane
    Ozguroglu, Mustafa
    Hansen, Steinbjorn
    Machiels, Jean-Pascal
    Kocak, Ivo
    Gravis, Gwenaelle
    Bodrogi, Istvan
    Mackenzie, Mary J.
    Shen, Liji
    Roessner, Martin
    Gupta, Sunil
    Sartor, A. Oliver
    LANCET, 2010, 376 (9747): : 1147 - 1154
  • [9] ProBio II: An adaptive and randomized multi-arm biomarker driven phase 2 study in men with castrate resistant prostate cancer (CRPC).
    Gronberg, Henrik
    Eklund, Martin
    Lindberg, Johan
    Ullen, Anders
    Bjartell, Anders
    Andren, Ove
    Robinson, David
    Lissbrant, Ingela Franck
    Enblad, Gunilla
    Stahl, Olof
    Thellenberg, Camilla
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [10] Efficacy and safety of apalutamide in patients with metastatic castration-resistant prostate cancer (GENESIS): protocol for a multicentre, open-label, single-arm clinical trial
    Miyake, Hideaki
    Kakei, Yasumasa
    Nakano, Yuzo
    Terakawa, Tomoaki
    Miyakoda, Keiko
    Harada, Kenichi
    Fujisawa, Masato
    BMJ OPEN, 2023, 13 (03):
12345